Phase 3Completed

MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H5: MP0420)

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Enrollment
485 enrolled
Conditions
COVID-19
Interventions
MP0420; Placebo; Remdesivir
Ages
adults, older adults
Registry
NCT05780463

Full record on ClinicalTrials.gov

From the registry

This study looks at the safety and effectiveness of MP0420 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either MP0420 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H5.

Primary outcomes

  • Number of Participants With Sustained Recovery
  • Number of Participants With an Ordinal Outcome on Day 5

History

  1. Results first posted

  2. Last registry update

  3. Study completion

  4. Registered

  5. Primary completion

  6. Started